You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: Technology Commercialization Partners LLC Topic: NHLBI
ABSTRACT Pulmonary hypertension (PH) is a highly debilitating disease that affects about 1% of the global population, which increases up to 10% in individuals aged more than 65 years. The life expectancy for these patients is less than 10 years after diagnosis, and no specific drugs are available for pharmacologic treatment. Despite the introduction PDE5, prostacyclin analogs, and endothelin antag ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: SEACOAST SCIENCE, INC. Topic: NIEHS
Perfluoroalkyl substances (PFAS) such as perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate) are toxic and persistent compounds resulting from the production and use of fluoropolymers such as Gortex® and Teflon ®. The structure of PFAS preclude environmental degradation and can lead to bioaccumulation in animals and humans. Reported adverse effects of these compounds in humans include: ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: Planet Biotechnology Incorporated Topic: 300
Urinary tract infections (UTIs) are among the most common bacterial infections, affecting 150 million people worldwide each year. In the USA, community-acquired UTIs account for about 11 million cases each year that cost the U.S. public health budget $5 billion annually. Uropathogenic Escherichia coli (UPEC) accounts for up to 80% of UTIs. While UTIs are currently treated with antibiotics, the fre ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: REELIN THERAPEUTICS, INC. Topic: 300
Abstract Factors that contribute to the onset of inflammatory bowel disease (IBD) remain incompletely understood. Although specific genetic factors may increase risk, most IBD cannot be readily explained based on genetics. Dysbiosis in intestinal microbiomes also has been implicated. Once IBD is established, chronic inflammation is a central hallmark and also a major target for therapy. Both forms ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
Development of an irreversible covalent inhibitor of FMS-like tyrosine kinase receptor 3 for treating acute myeloid leukemiaSBC: BRIDGENE BIOSCIENCES INC Topic: 102
PROJECT SUMMARY Acute myeloid leukemia (AML), a malignant disease of hematopoietic precursor cells in the bone marrow, is one of the most common cancers in adults accounting for 1% of all cancers. AML is typically diagnosed later in life with individuals 60 and older having a long-term survival rate of merely 5-15%. Cytogenic analysis of the abnormal cells at the time of diagnosis has proven to be ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
Preventing liver fibrosis in alcoholic hepatitis by enhancing liver regenerative capacity via transient telomere extension using lipid nanoparticle-encapsulated TERT mRNASBC: REJUVENATION TECHNOLOGIES INC Topic: 400
Abstract Rejuvenation Technologies Inc. (RTI) aims to prevent liver fibrosis in alcoholic hepatitis (AH) by enhancing liver regenerative capacity. AH is an acute form of alcoholic liver disease with mortality of up to 50% within 1 month of presentation. Most AH patients exhibit advanced fibrosis/cirrhosis, which contributes to acute-on-chronic liver failure. RTI will ameliorate/prevent this fibros ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: Storx Technologies, Inc. Topic: NICHD
Project Summary Despite significant cost and clear evidence of health risks associated with Cesarean section surgeries, an unnecessarily large number of infants are delivered via Cesarean section (C- Section) surgeries. The high rate of C-section in the US, relative to globally accepted norms, and the associated additional cost and complications are in part, due to high false positive rate of intr ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: Wildflower Biopharma Inc Topic: 102
Project Summary/Abstract Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in Western countries. Despite recent treatment advances, CLL remains incurable. In the era of emerging targeted therapies, disease progression and relapse increasingly are key challenges faced by CLL patients. Therefore, there is an ongoing need for the identification of targetable vulnerabilities in t ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
Portable Affordable Innovative and Smart Device-Coupled Electronic Fetal Monitoring System to Improve Rural Access to Obstetrics Services and Improve Outcomes in Rural CommunitiesSBC: Fetal Life, LLC Topic: 102
Obstetricians measure fetal heartrate (FHR) and uterine contractions to evaluate fetal health during pregnancy and labor. This monitoring is performed to decrease the development of complications while minimizing the need for unnecessary obstetric interventions and is especially important for women with high-risk pregnancies. However, many women, especially in rural areas, do not have the time or ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: WinSanTor, Inc. Topic: NINDS
PROJECT SUMMARY An estimated 30 million people in the United States suffer from some form of peripheral neuropathy, a condition that develops as a result of damage to the peripheral nervous system. The top two major causes of peripheral neuropathy in the US are diabetes mellitus (both T1DM and T2DM) and chemotherapeutic agents. Currently, there are no FDA-approved treatments to prevent or reverse ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health